XERS Stock News & Catalysts – Xeris Biopharma

FEATURED

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

Total revenue increased 44% year-over-year to $107 million Recorlev net revenue increased 93% year-over-year to more than $71 million Raises full-year 2026 total revenue guidance to $395 million to $405

Summary

Nov 5, 2026, 7:00 AM ·Business Wire

RECENT

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

Experienced biopharmaceutical executive brings global commercial leadership, financial expertise, and public company governance experience Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a leading endocrine and rare

Nov 2, 2026, 8:00 AM ·Business Wire

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Conference call and audio webcast to be held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better

Oct 22, 2026, 8:00 AM ·Business Wire

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including

Oct 15, 2026, 8:00 AM ·Business Wire

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today

Oct 2, 2026, 5:00 PM ·Business Wire

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to

Sep 9, 2026, 8:30 AM ·Business Wire

Xeris Announces Details for XP-8121 Program Overview Webinar

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to

Aug 26, 2026, 7:30 AM ·Business Wire

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81% year-over-year to approximately $57 million Tightens full-year

Aug 6, 2026, 7:00 AM ·Business Wire

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Conference Call to be Held at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative

Jul 23, 2026, 7:30 AM ·Business Wire

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT

Jul 2, 2026, 4:05 PM ·Business Wire

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jul 2, 2026, 4:05 PM ·Business Wire

Xeris Announces Updates to Its Board of Directors

Chief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July 1, 2026 Xeris Biopharma

Jun 30, 2026, 7:00 AM ·Business Wire

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris' commitment to the primary periodic paralysis community and the patients who rely on Keveyis Xeris

Jun 11, 2026, 4:39 PM ·Business Wire

Xeris Biopharma Announces Private Exchange of Convertible Notes

Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a

Jun 11, 2026, 7:00 AM ·Business Wire

Xeris Biopharma Reports First Quarter 2026 Financial Results

Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390

May 7, 2026, 7:00 AM ·Business Wire

Xeris Biopharma Holdings, Inc. XERS · News